Yes, add aspirin to clopidogrel immediately in this patient with ischemic cardiomyopathy and new chest pain
In a patient with known ischemic cardiomyopathy presenting with new chest pain concerning for acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel should be initiated immediately while awaiting laboratory results. This represents presumed ACS until proven otherwise, and the FDA labeling explicitly states that clopidogrel should be administered in conjunction with aspirin for ACS patients 1.
Rationale for Immediate DAPT
The clinical scenario describes new-onset chest pain in a patient with established coronary disease—this is ACS until proven otherwise. The FDA-approved indication for clopidogrel specifically states it should be used "in conjunction with aspirin" for patients with non-ST elevation ACS (unstable angina/NSTEMI), including those managed medically 1. The 2016 ACC/AHA guidelines reinforce that aspirin remains the cornerstone of antiplatelet therapy in ACS patients, with additional P2Y12 inhibition (clopidogrel) providing a 21% absolute reduction in subsequent ischemic events 2.
Key action points:
- Start aspirin 75-325 mg daily immediately (if not already on it)
- Continue clopidogrel 75 mg daily (already prescribed)
- If rapid antiplatelet effect needed and patient not already loaded, consider clopidogrel 300 mg loading dose 1
Evidence Supporting This Approach
The CURE trial demonstrated that in patients with non-ST elevation ACS, adding clopidogrel to aspirin reduced cardiovascular death, MI, or stroke from 11.4% to 9.3% (20% relative risk reduction, p<0.001) 2. This benefit was observed regardless of whether patients were managed medically or with revascularization, and the majority of benefit occurred within the first two months 2.
The 2016 ACC/AHA guidelines recommend at least 12 months of DAPT for patients with ACS, whether treated with PCI, CABG, or medical therapy alone 2. This duration applies even to patients managed conservatively without revascularization.
Heart Failure Considerations
The presence of HFrEF does not contraindicate DAPT in this setting. While there has been historical controversy about aspirin in heart failure patients, the WARCEF trial (2,305 patients with HFrEF, 98.6% on ACE inhibitor/ARB) found no significant increase in heart failure events with aspirin compared to warfarin 3. The concern about aspirin interfering with ACE inhibitor benefits through prostaglandin inhibition has not translated into clinically significant harm in modern trials 3.
The PLUTO-CHF trial specifically demonstrated that clopidogrel plus aspirin provides significantly greater platelet inhibition than aspirin alone in heart failure patients, with no deaths, hospitalizations, or serious adverse events during the study period 4. This antiplatelet benefit is uniform across different heart failure etiologies, NYHA classes, and ejection fractions 5.
Bleeding Risk Assessment
The main concern with DAPT is bleeding risk. The CURE trial showed a 10% absolute increase in major bleeding with clopidogrel plus aspirin 2. However, in the acute setting of suspected ACS, the mortality and morbidity benefit from preventing thrombotic events outweighs bleeding risk in most patients.
Contraindications to immediate DAPT:
- Active pathological bleeding (peptic ulcer, intracranial hemorrhage) 1
- Known hypersensitivity to aspirin or clopidogrel 1
- Concurrent oral anticoagulation (requires careful risk-benefit assessment and close monitoring) 6
Monitoring and Next Steps
While awaiting troponin and ECG results:
- Continue DAPT
- Monitor for bleeding complications
- If ACS is confirmed, plan for at least 12 months of DAPT 2
- If ACS is ruled out and patient has stable ischemic heart disease with prior MI, aspirin monotherapy may be sufficient long-term, though DAPT continuation could be considered 6
Important caveat: If the patient is a CYP2C19 poor metabolizer (2% of Whites, 4% of Blacks, 14% of Chinese), clopidogrel will have reduced efficacy, and alternative P2Y12 inhibitors (prasugrel or ticagrelor) should be considered if ACS is confirmed 1.
The nighttime pattern of chest pain does not change the management—any new chest pain in a patient with ischemic cardiomyopathy warrants presumptive ACS treatment until proven otherwise.